Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Myeloid 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Melanoma 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Merkel Cell 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Thymoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Microsatellite Instability 1Mesothelioma 1

Interventions

Gemcitabine 4tazemetostat 2pembrolizumab 2Rituximab 2Itraconazole 2Cyclophosphamide 2Cisplatin 2vandetanib 1utomilumab 1temsirolimus 1sargramostim 1ruxolitinib 1motexafin gadolinium 1motesanib diphosphate 1fludarabine 1enzalutamide 1entinostat 1carboxyamido-triazole 1avelumab 1Watchful Waiting 1Vorinostat 1Topotecan 1Thalidomide 1Ritonavir 1Rifampin 1Radiotherapy 1Polymerase Chain Reaction 1Pemetrexed 1Paclitaxel 1PF06821497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × avelumab × Thoracic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡